Sagefield Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sagefield Capital’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,300	Closed	-$497K	–	146
2022 Q3	$497K	Buy	+7,300	New	+$403K	0.16%	89

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sagefield Capital's GBT Position: Q4 2022 in Review

Sagefield Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 7,300 shares — an estimated $497K sold.

Sagefield Capital first reported a position in GBT in Q3 2022 and held it in 1 quarter. The position peaked at $497K in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Sagefield Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Sagefield Capital sold 7,300 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $497K.
Sagefield Capital first reported a position in Global Blood Therapeutics, Inc. in Q3 2022 and held it in 1 quarter.
Sagefield Capital's Global Blood Therapeutics, Inc. position peaked at $497K in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Sagefield Capital's 13F filing for Q4 2022, filed 14 Feb 2023.